Step 1 topics → Biochemistry → Heme Synthesis and Porphyrias

Heme Synthesis and Porphyrias

USMLE Step 1 trap: Confuses AIP (neurovisceral, no skin findings) with PCT (cutaneous blistering, no neurological symptoms). AIP causes neurovisceral attacks (abdominal pain, neuropsychiatric symptoms, autonomic dysfunction) without cutaneous findings; PCT causes blistering photosensitivity without neurological symptoms.

Heme synthesis is a high-yield biochemistry pathway that USMLE Step 1 tests repeatedly — not just as pathway recall but as clinical application. You need to know where synthesis starts (mitochondria, with ALA synthase), where it continues (cytoplasm), and where it finishes (back in mitochondria with ferrochelatase). The exam loves to disguise porphyria questions inside clinical vignettes with abdominal pain, psychiatric symptoms, or blistering skin — and students who haven't locked down the clinical features get them wrong every time.

The trickiest part of this topic is distinguishing the porphyrias from each other. Acute intermittent porphyria (AIP) and porphyria cutanea tarda (PCT) are both tested heavily, but they look completely different clinically. AIP has zero skin findings — it's all neurovisceral. PCT has zero neurological symptoms — it's all blistering skin in sun-exposed areas. Students who blur this line get burned on vignette questions. Lead poisoning adds another layer because it mimics some porphyria lab findings while having its own distinct clinical picture.

USMLE Step 1 also tests the regulatory logic of the pathway — specifically, what feedback-inhibits what, and which enzymes lead knocks out. These aren't arbitrary details; they're the mechanistic anchors that let you reason through novel presentations. Students who memorize facts without the mechanism struggle when the question is phrased from an unexpected angle, like asking what accumulates upstream when a specific enzyme is blocked.

From real student decks
95%have cards covering this topic
62%have mature cards

Common misconceptions

Common mistake
Wrong: Acute intermittent porphyria (AIP) causes photosensitivity like porphyria cutanea tarda (PCT).
Right: AIP causes neurovisceral attacks (abdominal pain, neuropsychiatric symptoms, autonomic dysfunction) without cutaneous findings; PCT causes blistering photosensitivity without neurological symptoms.
AIP and PCT are both porphyrias but they affect completely different organ systems. AIP accumulates ALA and porphobilinogen — precursors that are neurotoxic — producing abdominal pain, weakness, confusion, and autonomic instability with no photosensitive skin disease. PCT accumulates uroporphyrinogen, which is a photosensitizer, causing blistering of sun-exposed skin with no neurological involvement. Think of them as mutually exclusive presentations: if there's skin, it's not AIP; if there's neuro, it's not PCT.
Common mistake
Wrong: Lead poisoning inhibits only one enzyme in heme synthesis.
Right: Lead inhibits two enzymes in heme synthesis: ALA dehydratase (early step) and ferrochelatase (final step inserting iron into protoporphyrin IX).
Lead doesn't just knock out one step — it hits the pathway at two points simultaneously. It inhibits ALA dehydratase early in the pathway, causing ALA to accumulate, and it inhibits ferrochelatase at the very end, preventing iron incorporation into protoporphyrin IX and causing protoporphyrin IX to pile up. This dual blockade explains why you see both elevated ALA in urine and elevated free erythrocyte protoporphyrin on labs — knowing both targets helps you interpret lead toxicity questions correctly.
Common mistake
Wrong: Heme synthesis is regulated by feedback inhibition of ferrochelatase.
Right: Heme synthesis is regulated by feedback inhibition of ALA synthase (ALAS), the rate-limiting enzyme, by the end product heme.
Ferrochelatase is the last enzyme in the pathway, not the regulatory one. Feedback inhibition works at the committed, rate-limiting first step — which is ALA synthase (ALAS). When heme accumulates, it directly inhibits ALAS, shutting down the whole pipeline from the top. This is the same logic the AIP treatment exploits: IV hemin replenishes heme levels, which then suppresses ALAS activity and stops the toxic precursor buildup.
Common mistake
Gap: Misses that AIP is treated with IV hemin and glucose, and that P450-inducing drugs are key triggers to avoid
AIP attacks are treated with IV hemin (which replenishes heme and suppresses ALAS) and high-dose glucose, while triggers such as cytochrome P450-inducing drugs, fasting, and alcohol must be avoided.
AIP attacks are driven by upregulation of ALAS — the rate-limiting enzyme — leading to toxic precursor accumulation. Treatment targets this directly: IV hemin provides exogenous heme to feedback-inhibit ALAS, and high-dose glucose (or carbohydrate loading) also suppresses ALAS via its own regulatory mechanism. Equally important is trigger avoidance — cytochrome P450-inducing drugs (rifampin, barbiturates, carbamazepine, etc.) massively upregulate hepatic ALAS because heme is required for CYP enzyme synthesis, and fasting and alcohol both similarly induce the enzyme.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the full heme synthesis pathway: where it starts (mitochondria), where it moves to (cytoplasm), where it ends (mitochondria), which step is rate-limiting (ALA synthase), and how the end product heme feeds back to inhibit that rate-limiting step.
  2. Identify acute intermittent porphyria (AIP) by its neurovisceral triad — episodic abdominal pain, neuropsychiatric symptoms, and autonomic dysfunction — recognize its classic triggers (P450-inducing drugs, fasting, alcohol), and know that treatment is IV hemin plus high-dose glucose.
  3. Recognize porphyria cutanea tarda (PCT) by its cutaneous blistering photosensitivity in sun-exposed areas, understand it results from uroporphyrinogen decarboxylase deficiency, and know it has no neurological component.
  4. Identify the two heme synthesis enzymes that lead inhibits — ALA dehydratase and ferrochelatase — and connect this to the specific lab findings and clinical features that result from each blockade.

Can you avoid these mistakes?

A 28-year-old woman presents with three episodes of severe abdominal pain over the past year, each lasting several days and associated with confusion and urinary retention. Urine turns dark on standing. She recently started oral contraceptives. What is the diagnosis, what enzyme is deficient, and what change in her medications is most important?
On a biochemistry exam question, you're asked: 'Heme synthesis is feedback-inhibited at which step, and by which molecule?' What is the correct answer — and why would it be wrong to say ferrochelatase is the regulated enzyme?
A child with a history of eating paint chips from an old house has microcytic anemia and elevated free erythrocyte protoporphyrin. Name the two enzymes inhibited by lead in heme synthesis and explain what accumulates as a result of each blockade.
Two patients are referred to dermatology. Patient A has blistering vesicles on the backs of both hands after gardening; Patient B has severe abdominal cramping, weakness, and dark urine but no skin findings. Which porphyria fits each patient, what is the key enzyme defect in each, and which patient is at risk for neurological deterioration?

Related topics

TCA (Krebs) Cycle Nucleotide and Nucleic Acid Structure DNA Replication DNA Repair Pathways Mutations and Their Consequences

See how your Anki deck covers this topic.

Upload your deck for a free audit →